<DOC>
	<DOCNO>NCT00816465</DOCNO>
	<brief_summary>This clinical study design evaluate safety oral administration medical food Hoodia patient non alcoholic fatty liver disease . Oral administration Hoodia common many western world country appetite suppression food supplement medical food use dietary purpose . Nonalcoholic steatohepatitis NASH common , often `` silent '' liver disease affect 2 % -5 % Americans . NASH strongly associate metabolic syndrome , diabetes type-2 obesity lead cirrhosis , HCC , liver transplantation death.This clinical trial design assess safety short term oral administration Hoodia patient NASH .</brief_summary>
	<brief_title>Safety Efficacy Hoodia Gordonii Treatment Non Alcoholic Fatty Liver Disease ( NAFLD )</brief_title>
	<detailed_description />
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Fatty Liver</mesh_term>
	<mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
	<criteria>Subjects complete informed consent process culminate write informed consent subject Men woman age 18 65 year inclusive . Patients biopsy proven NASH score 4 . Altered glucose metabolism , include diabetes ( non treat , treat 2 drug ( include insulin ) without change medication 2 month prior enrolment ) , impaired fast glucose impair glucose tolerance . HBA1C 5.5 14 % .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2010</verification_date>
	<keyword>Hoodia gordoni</keyword>
	<keyword>NASH</keyword>
	<keyword>NAFLD</keyword>
</DOC>